Phase 2: Valuation Without the Bias -- 💥 Coming Soon 💥
👉. Once the Forensic Jury confirms a company is fundamentally healthy, the question becomes price. Is it cheap, fair, or overpriced? Today, we only tell you whether a firm is healthy, but soon we can help you understand if the price is right. Occam's Investing deploys two independent AI valuation analysts — Claude and Perplexity — each running a rigorous, data-driven valuation from a clean slate, with no agenda and no career risk. When they agree, you get a high-conviction signal. When they diverge, Gemini steps in as the tiebreaker — a third perspective with no prior position to defend. No single analyst. No single model. No single point of failure. Just three forensic minds working the same problem independently, then reconciling. The result isn't a price target handed down from a Wall Street firm that owns shares in the company it's rating. It's a systematic valuation built the way you'd want it built — transparent, reproducible, and completely free of human narrative. ✅